Sign In
Buy SNGX
$0.483
-0.266 (-35.48%)
At Close: Jun 03, 2026
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
07:30am, Thursday, 14'th Aug 2025
PRINCETON, N.J. , Aug. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer
08:30am, Friday, 08'th Aug 2025
AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therap
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
07:30am, Thursday, 31'st Jul 2025
Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J. , July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage
Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
07:30am, Tuesday, 08'th Jul 2025
PRINCETON, N.J. , July 8, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
07:30am, Tuesday, 01'st Jul 2025
Active Ingredient Manufacturing Transfer to the U.S. Complete PRINCETON, N.J. , July 1, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutica
Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
09:37am, Friday, 06'th Jun 2025
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializi
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
07:30am, Friday, 09'th May 2025
PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
07:30am, Monday, 14'th Apr 2025
Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or t
IBN Initiates Coverage of Soligenix Inc.
08:30am, Tuesday, 25'th Mar 2025
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare dis
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
07:30am, Tuesday, 25'th Mar 2025
Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™ compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March 25, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasd
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
07:30am, Friday, 21'st Mar 2025
PRINCETON, N.J. , March 21, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products t
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
07:30am, Thursday, 06'th Mar 2025
Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J. , March 6, 2025 /PRNewswire/ -- Soligenix, Inc.
Soligenix to Present at BIO CEO & Investor Conference
07:30am, Tuesday, 04'th Feb 2025
PRINCETON, N.J. , Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t
Soligenix to Present at Upcoming Investor Conferences
07:30am, Thursday, 16'th Jan 2025
PRINCETON, N.J. , Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
07:30am, Tuesday, 14'th Jan 2025
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Jan. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmac
